These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19898180)

  • 1. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
    Engelbert M; Zweifel SA; Freund KB
    Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
    Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
    Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
    Zweifel SA; Engelbert M; Khan S; Freund KB
    Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum.
    Myung JS; Bhatnagar P; Spaide RF; Klancnik JM; Cooney MJ; Yannuzzi LA; Freund KB
    Retina; 2010 May; 30(5):748-55. PubMed ID: 19996818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
    Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
    Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
    Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
    Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
    Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE
    Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.